New scan could reveal where cancer drugs go in the body
NCT ID NCT07221825
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new imaging technique called low-count quantitative SPECT (LC-QSPECT) to see how the drug Radium-223 spreads in men with advanced prostate cancer. About 38 men who are already eligible for Radium-223 will get extra scans after their treatment. The goal is to see if this scan can reliably measure drug uptake in tumors and organs, which could help doctors personalize treatment in the future.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Low-count quantitative single-photon emission computed tomography (LC-QSPECT) imaging
What this could lead to
If successful, this imaging method could help doctors see where Radium-223 goes in the body, potentially leading to better personalized treatment for prostate cancer.
What could go wrong
This is a very early feasibility study with only 38 participants. The imaging technique is new and may not provide clear enough results to change practice.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Contact
Contact
Contact
Contact
Contact